An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Modified And Immediate Release Formulations In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs CE 224535 (Primary)
- Indications Osteoarthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 08 Apr 2009 Planned number of patients changed from 24 to 11 as reported by ClinicalTrials.gov.
- 08 Apr 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.